Sabin polio virus protein 1 (VP1) evolution in patients with acute faccid paralysis from 2010 to 2016 in Uganda

Simple item page
dc.contributor.authorMary Bridget Nanteza
dc.contributor.authorBakamutumaho, Barnabas
dc.contributor.authorTushabe, Phionah
dc.contributor.authorNamuwulya, Prossy
dc.contributor.authorBirungi, Molly
dc.contributor.authorDhatemwa, Rajab
dc.contributor.authorEliku, James Peter
dc.contributor.authorTibanagwa, Mayi
dc.contributor.authorKakooza, Proscovia
dc.contributor.authorBukenya, Henry
dc.contributor.authorBwogi, Josephine
dc.contributor.authorByabamazima, Charles Rutebarika
dc.date.accessioned2025-03-09T17:35:46Z
dc.date.available2025-03-09T17:35:46Z
dc.date.issued2023
dc.description.abstractAcute flaccid paralysis (AFP) is a rare side effect of the oral polio vaccine but can be associated with outbreaks and permanent disability in patients harboring circulating vaccine-derived polioviruses (cVDPVs). With the advancement of polio abolition in a glimpse, cVDPVs are causing outbreaks and slowing the polio eradication process. The polio virus protein 1 (VP1) contains the binding site that is key for virus transmission. Understanding the evolution of VP1 among AFP patients could yield more insight into the early events of cVDPVs. Polioviruses were identified from stool specimens of AFP patients using cell culture; and confirmed by the real time RT PCR intra-typic differentiation and vaccine-derived poliovirus assays. Seventy-nine (79) Sabin-like poliovirus 1 (SL1) and 86 Sabin-like poliovirus 3 (SL3) were sequenced. The VP1 amino acid substitutions T106A in Sabin poliovirus 1 and A54V in Sabin poliovirus 3 were common among the AFP patients as has been found in previous studies. Other substitutions that were associated with AFP were: T290A and A54T in SL1 and SL3 respectively. Nucleotide mutations that were common among the AFP patients included T402C, C670A, and T816C in SL1, and G22A, C375Y, A472R, and A694T in SL3 polioviruses. Characterizing mutations that are associated with AFP could contribute to efforts pursued to mitigate the risk of vaccine-derived polioviruses and promote development of safer vaccines.
dc.identifier.citationNanteza, M. B., Bakamutumaho, B., Tushabe, P., Namuwulya, P., Birungi, M., Dhatemwa, R., ... & Byabamazima, C. R. (2023). Sabin polio virus protein 1 (VP1) evolution in patients with acute flaccid paralysis from 2010 to 2016 in Uganda. Virology Journal, 20(1), 172. https://doi.org/10.1186/s12985-023-02143-7
dc.identifier.urihttps://doi.org/10.1186/s12985-023-02143-7
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/10093
dc.language.isoen
dc.publisherVirology Journal
dc.titleSabin polio virus protein 1 (VP1) evolution in patients with acute faccid paralysis from 2010 to 2016 in Uganda
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Sabin polio virus protein 1 (VP1) evolution.pdf
Size:
1.19 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences